Abstract
Single oral doses of the central and peripheral nicotinic antagonist mecamylamine were administered to healthy young normal males in doses of 5, 10, and 20 mg in a placebo-controlled, double-blind study. The 20 mg dose caused a significant increase in errors in the learning condition of the Repeated Acquisition task, producing a slower acquisition curve. The lower doses produced less errors, but more than in the placebo condition. There was no effect of drug on the performance component (retrieval of previously learned information). On the recognition memory task, dose-related increases in false-alarms during the delay period were seen, with little effect on misses or hits. Reaction time measures suggested a dose-related slowing of RT on several tasks. Behavioral effects were minimal and physiologic measures were consistent with dose-related ganglionic blockade. We interpret these results to indicate that acute blockade of nicotinic receptor function can produce measurable and significant cognitive impairment, even in non-smoking normals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartus R, Dean R, Beer B, Lippa A (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417
Buschke H, Fuld P (1974) Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24:1019–1025
Corwin J, Peselow E, Fieve R, Rotrosen J (1987) Memory in untreated depression: severity and task requirement effects. Presented at ACNP Annual Meeting, December, San Juan
Drachman D (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27:783–790
Drachman D, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113–121
Elrod K, Buccafusco J (1991) Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 258:403–409
Elrod K, Bucafusco J, Jackson W (1988) Nicotine enhances delayed match-to-sample performance by primates. Life Sci 43:277–281
Flynn D, Mash D (1986) Characterization of 1-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 47:1948–1954
Fuld P, Katzman R, Davies P, Terry RD (1982) Intrusions as a sign of Alzheimer dementia: chemical and pathological verification. Ann Neurol 11:155–159
Giacobini E (1990) Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurosci Res 27:548–560
Gitelman DR, Prohovnik I (1992) Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging (in press)
Higgins ST, Woodward BM, Henningfield JE (1989) Effects of atropine on the repeated acquisition and performance of response sequences in humans. J Exp Anal Behav 51:5–15
Ksir C, Benson D (1983) Enhanced behavioral response to nicotine in an animal model of Alzheimer's disease. Psychopharmacology 81:272–273
Martin BR, Onaivi ES, Martin TJ (1989) What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 38:3391–3397
Nelson JM, Goldstein L (1972) Improvement of performance on an attention task with chronic nicotine treatment in rats. Psychopharmacologia 26:347–360
Newhouse P, Sunderland T, Tariot P, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175
Newhouse P, Sunderland T, Narang P, Mellow AM, Fertig JB, Lawlor BA, Murphy DL (1990) Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and patients with Alzheimer's disease. Psychoneuroendocrinology 15:471–484
Nordberg A, Bergh C (1985) Effect of nicotine on passive-avoidance behavior and motoric activity in mice. Acta Pharmacol Toxicol 56:337–341
Nordberg A, Nilsson-Håkansson, Adem A, Hardy J, Alafuzoff I, Lai Z, Herrera-Marschitz M, WInblad B (1989) The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 79:353–362
O'Dell TJ, Christensen BN (1988) Mecamylamine is a selective non-competitive antagonist of n-methyl-d-aspartate- and aspartate-induced currents in horizontal cells dissociated from catfish retina. Neurosci Lett 94:93–98
Overall J, Gorham D (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer's and Parkinson's disease. J Neurol Neurosurg Psychiatry 50:806–809
Pickworth WB, Herning RI, Henningfield JE (1988) Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol Biochem Behav 30:149–153
Pomerleau C, Pomerleau O, Majchrzak M (1987) Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology 91:391–393
Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800
Snell LD, Johnson KM (1989) Effects of nicotinic agonists and antagonists on n-methyl-d-aspartate-induced3H-norepinephrine release and3H-(1-[1-(2-thienyl)cyclohexyl]-piperidine) binding in rat hippocampus. Synapse 3:129–135
Snodgrass J, Corwin J (1988) Pragmatics of recognition memory: application to dementia and amnesia. J Exp Psychol [Gen] 117:34–50
Snyder FR, Henningfield JE (1989) Effects of nicotine administration following 12 hours of tobacco deprivation: assessment on computerized performance tasks. Psychopharmacology 97:17–22
Stolerman I, Goldfarb T, Fink R, Jarvik M (1973) Influencing cigarette smoking with nicotine antagonists. Psychopharmacology 28:247–259
Sunderland T, Tariot PN, Newhouse PA (1989) Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 13:371–389
Thompson D (1973) Repeated acquisition as a behavioral base line for studying drug effects. J Pharmacol Exp Ther 184:506–514
Thorne D, Genser S, Sing H, Hegge F (1985) The Walter Reed performance assessment battery. Neurobehav Toxicol Teratol 7:415–418
Van Kammen D, Murphy D (1975) Attenuation of the euphoriant and activating effects ofd- andl-amphetamine by lithium carbonate treatment. Psychopharmacology 44:215–224
Wesnes K, Warburton D (1983) Smoking, nicotine, and human performance. Pharmacol Ther 21:189–208
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, De Long MR (1982) Alzheimer's disease and senile dementia-loss of neurons in the basal forebrain. Science 215:1237–1239
Whitehouse P, Martino A, Antuono P, Kellar K (1986) Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371:146–151
Author information
Authors and Affiliations
Additional information
This work was supported by NIMH grant R29-46625 to P.N. and by GCRC M01-00109.
Rights and permissions
About this article
Cite this article
Newhouse, P.A., Potter, A., Corwin, J. et al. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108, 480–484 (1992). https://doi.org/10.1007/BF02247425
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02247425